Adient (ADNT) reported $3.66 billion in revenue for the quarter ended December 2023, representing a year-over-year decline of 1.1%. EPS of $0.31 for the same period compares to $0.34 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $3.72 billion, representing a surprise of -1.50%. The company delivered an EPS surprise of -34.04%, with the consensus EPS estimate being $0.47.
While investors closely watch year-over-year changes in headline numbers — revenue and earnings — and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company’s underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock’s price performance more accurately.
Here is how Adient performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
-
Net Sales- Asia: $770 million versus $844.49 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -6.2% change.
-
Net Sales- Eliminations: -$25 million versus the two-analyst average estimate of -$32.69 million. The reported number represents a year-over-year change of -10.7%.
-
Net Sales- America: $1.65 billion versus the two-analyst average estimate of $1.64 billion. The reported number represents a year-over-year change of -4.5%.
-
Net Sales- EMEA: $1.27 billion versus the two-analyst average estimate of $1.25 billion. The reported number represents a year-over-year change of +7.3%.
View all Key Company Metrics for Adient here>>>
Shares of Adient have returned +4.7% over the past month versus the Zacks S&P 500 composite’s +5.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Adient (ADNT) : Free Stock Analysis Report